These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 16764346)

  • 1. The new global multiple sclerosis severity score (MSSS) correlates with axonal but not glial biomarkers.
    Petzold A; Eikelenboom MI; Keir G; Polman CH; Uitdehaag BM; Thompson EJ; Giovannoni G
    Mult Scler; 2006 Jun; 12(3):325-8. PubMed ID: 16764346
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Acute axonal damage predicts clinical outcome in patients with multiple sclerosis.
    Lim ET; Sellebjerg F; Jensen CV; Altmann DR; Grant D; Keir G; Thompson EJ; Giovannoni G
    Mult Scler; 2005 Oct; 11(5):532-6. PubMed ID: 16193890
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cerebrospinal fluid brain specific proteins in relation to nitric oxide metabolites during relapse of multiple sclerosis.
    Rejdak K; Petzold A; Stelmasiak Z; Giovannoni G
    Mult Scler; 2008 Jan; 14(1):59-66. PubMed ID: 17893112
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Axonal damage accumulates in the progressive phase of multiple sclerosis: three year follow up study.
    Petzold A; Eikelenboom MJ; Keir G; Grant D; Lazeron RH; Polman CH; Uitdehaag BM; Thompson EJ; Giovannoni G
    J Neurol Neurosurg Psychiatry; 2005 Feb; 76(2):206-11. PubMed ID: 15654034
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of repeated intrathecal triamcinolone-acetonide application on cerebrospinal fluid biomarkers of axonal damage and glial activity in multiple sclerosis patients.
    Rommer PS; Kamin F; Petzold A; Tumani H; Abu-Mugheisib M; Koehler W; Hoffmann F; Winkelmann A; Benecke R; Zettl UK
    Mol Diagn Ther; 2014 Dec; 18(6):631-7. PubMed ID: 24986188
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Axonal damage in the making: neurofilament phosphorylation, proton mobility and magnetisation transfer in multiple sclerosis normal appearing white matter.
    Petzold A; Tozer DJ; Schmierer K
    Exp Neurol; 2011 Dec; 232(2):234-9. PubMed ID: 21958956
    [TBL] [Abstract][Full Text] [Related]  

  • 7. N-acetylaspartate and neurofilaments as biomarkers of axonal damage in patients with progressive forms of multiple sclerosis.
    Trentini A; Comabella M; Tintoré M; Koel-Simmelink MJ; Killestein J; Roos B; Rovira A; Korth C; Ottis P; Blankenstein MA; Montalban X; Bellini T; Teunissen CE
    J Neurol; 2014 Dec; 261(12):2338-43. PubMed ID: 25228004
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phosphorylation and compactness of neurofilaments in multiple sclerosis: indicators of axonal pathology.
    Petzold A; Gveric D; Groves M; Schmierer K; Grant D; Chapman M; Keir G; Cuzner L; Thompson EJ
    Exp Neurol; 2008 Oct; 213(2):326-35. PubMed ID: 18619438
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Glial and neuroaxonal biomarkers in a multiple sclerosis (MS) cohort.
    Kalatha T; Hatzifilippou E; Arnaoutoglou M; Balogiannis S; Koutsouraki E
    Hell J Nucl Med; 2019; 22 Suppl 2():113-121. PubMed ID: 31802051
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A comparative study of CSF neurofilament light and heavy chain protein in MS.
    Kuhle J; Plattner K; Bestwick JP; Lindberg RL; Ramagopalan SV; Norgren N; Nissim A; Malaspina A; Leppert D; Giovannoni G; Kappos L
    Mult Scler; 2013 Oct; 19(12):1597-603. PubMed ID: 23529999
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Limiting multiple sclerosis related axonopathy by blocking Nogo receptor and CRMP-2 phosphorylation.
    Petratos S; Ozturk E; Azari MF; Kenny R; Lee JY; Magee KA; Harvey AR; McDonald C; Taghian K; Moussa L; Mun Aui P; Siatskas C; Litwak S; Fehlings MG; Strittmatter SM; Bernard CC
    Brain; 2012 Jun; 135(Pt 6):1794-818. PubMed ID: 22544872
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Serum phosphorylated neurofilament-heavy chain levels in multiple sclerosis patients.
    Gresle MM; Liu Y; Dagley LF; Haartsen J; Pearson F; Purcell AW; Laverick L; Petzold A; Lucas RM; Van der Walt A; Prime H; Morris DR; Taylor BV; ; Shaw G; Butzkueven H
    J Neurol Neurosurg Psychiatry; 2014 Nov; 85(11):1209-13. PubMed ID: 24639436
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Neurofilament protein in cerebrospinal fluid: a potential marker of activity in multiple sclerosis.
    Lycke JN; Karlsson JE; Andersen O; Rosengren LE
    J Neurol Neurosurg Psychiatry; 1998 Mar; 64(3):402-4. PubMed ID: 9527161
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Neurofilament light and heavy subunits compared as therapeutic biomarkers in multiple sclerosis.
    Kuhle J; Malmeström C; Axelsson M; Plattner K; Yaldizli O; Derfuss T; Giovannoni G; Kappos L; Lycke J
    Acta Neurol Scand; 2013 Dec; 128(6):e33-6. PubMed ID: 23763388
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Glial fibrillary acidic protein: a potential biomarker for progression in multiple sclerosis.
    Axelsson M; Malmeström C; Nilsson S; Haghighi S; Rosengren L; Lycke J
    J Neurol; 2011 May; 258(5):882-8. PubMed ID: 21197541
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cerebrospinal fluid immunological biomarkers associated with axonal damage in multiple sclerosis.
    Villar LM; Picón C; Costa-Frossard L; Alenda R; García-Caldentey J; Espiño M; Muriel A; Álvarez-Cermeño JC
    Eur J Neurol; 2015 Aug; 22(8):1169-75. PubMed ID: 25324032
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Chronic White Matter Inflammation and Serum Neurofilament Levels in Multiple Sclerosis.
    Maggi P; Kuhle J; Schädelin S; van der Meer F; Weigel M; Galbusera R; Mathias A; Lu PJ; Rahmanzadeh R; Benkert P; La Rosa F; Bach Cuadra M; Sati P; Théaudin M; Pot C; van Pesch V; Leppert D; Stadelmann C; Kappos L; Du Pasquier R; Reich DS; Absinta M; Granziera C
    Neurology; 2021 Aug; 97(6):e543-e553. PubMed ID: 34088875
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Combination of CSF N-acetylaspartate and neurofilaments in multiple sclerosis.
    Teunissen CE; Iacobaeus E; Khademi M; Brundin L; Norgren N; Koel-Simmelink MJ; Schepens M; Bouwman F; Twaalfhoven HA; Blom HJ; Jakobs C; Dijkstra CD
    Neurology; 2009 Apr; 72(15):1322-9. PubMed ID: 19365053
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Axonal degeneration as substrate of fractional anisotropy abnormalities in multiple sclerosis cortex.
    Preziosa P; Kiljan S; Steenwijk MD; Meani A; van de Berg WDJ; Schenk GJ; Rocca MA; Filippi M; Geurts JJG; Jonkman LE
    Brain; 2019 Jul; 142(7):1921-1937. PubMed ID: 31168614
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Axonal damage and outcome in subarachnoid haemorrhage.
    Petzold A; Keir G; Kay A; Kerr M; Thompson EJ
    J Neurol Neurosurg Psychiatry; 2006 Jun; 77(6):753-9. PubMed ID: 16705199
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.